Modulation of human Vα24+Vβ11+ NKT cells by age, malignancy and conventional anticancer therapies by Crough, T et al.
Modulation of human Va24
þVb11
þ NKT cells by age,
malignancy and conventional anticancer therapies
T Crough
1,2, DM Purdie
2, M Okai
2, A Maksoud
2, M Nieda
3 and AJ Nicol*,1,2,4
1Department of Medicine, University of Queensland, Brisbane, Australia;
2The Queensland Institute of Medial Research, Brisbane, Australia;
3Bone
Marrow Transplant Unit, Royal Brisbane Hospital, Brisbane, Australia;
4Yokohama City University School of Medicine, Japan
Immunotherapy strategies aimed at increasing human Va24
þVb11
þ natural killer T (NKT) cell numbers are currently a major focus.
To provide further information towards the goal of NKT cell-based immunotherapy, we assessed the effects of age, cancer status and
prior anticancer treatment on NKT cell numbers and their expansion capacity following a-galactosylceramide (a-GalCer) stimulation.
The percentage and absolute number of peripheral blood NKT cells was assessed in 40 healthy donors and 109 solid cancer patients
(colorectal (n¼33), breast (n¼10), melanoma (n¼17), lung (n¼8), renal cell carcinoma (n¼10), other cancers (n¼31)).
Responsiveness to a-GalCer stimulation was also assessed in 28 of the cancer patients and 37 of the healthy donors. Natural killer T
cell numbers were significantly reduced in melanoma and breast cancer patients. While NKT numbers decreased with age in healthy
donors, NKT cells were decreased in these cancer subgroups despite age and sex adjustments. Prior radiation treatment was shown
to contribute to the observed reduction in melanoma patients. Although cancer patient NKT cells were significantly less responsive to
a-GalCer stimulation, they remained capable of substantial expansion. Natural killer T cells are therefore modulated by age,
malignancy and prior anticancer treatment; however, cancer patient NKT cells remain capable of responding to a-GalCer-based
immenotherapies.
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Natural killer T (NKT) cells are a unique lymphocyte subset,
which in humans are characterized by the presence of an invariant
T-cell receptor (TCR) Va24
þVb11
þ associated with the natural
killer (NK) receptor NKR-P1A (Dellabona et al, 1994).
Unlike conventional T cells human NKT cells and their murine
counterpart, Va14 NKT cells are activated by the glycolipid,
a-galactosylceramide (a-GalCer) presented by a nonpoly-
morphic major histocompatability complex (MHC) class
I-like molecule CD1d (Kawano et al, 1999b; Nieda et al, 1999).
Natural killer T cells have been shown to have strong antitumour
activity upon a-GalCer stimulation (Kawano et al, 1998; Nicol
et al, 2000b; Kikuchi et al, 2001; Nieda et al, 2001). As
a consequence, clinical trials aimed at activating and increasing
NKT cell numbers are currently a major focus for immune therapy
of cancer.
There are limited studies detailing the normal range of human
peripheral blood (PB) NKT cells numbers and the effects of
parameters such as age, malignant disease and associated
treatment on their number and function. As the ageing process
and immune dysfunction due to malignant disease have been
shown to impact other cell types, these factors require considera-
tion for NKT cells (Goto et al, 1999; Ninomiya et al, 1999; Hakim
et al, 2004; Plackett et al, 2004).
The effect of the ageing process on NKT cell numbers has
only been assessed in a single study, where the percentage of
Va24
þ T cells was shown to decrease with age (DelaRosa
et al, 2002). The impact of age, however, on NKT cell expansion
following a-GalCer stimulation has not yet been evaluated
(DelaRosa et al, 2002). If NKT cells do contribute to the
normal protective mechanisms against cancer, a reduction in
NKT cell number or function as a result of the ageing process age
may contribute to the higher incidence of cancer in this group of
patients.
The effects of malignancy on NKT cell number and function
remain unclear. Significant reductions in PB NKT cell numbers
have been reported in patients with melanoma, prostate
cancer and lung cancer (Kawano et al, 1999a; Tahir et al, 2001;
Motohashi et al, 2002), however in other studies the numbers
of NKT cells in advanced cancer patients are comparable to
those in healthy individuals (Yanagisawa et al, 2002). Variations
in NKT cell function have also been described.
Decreased responsiveness of NKT cells to a-galactosylceramide
(a-GalCer) stimulation has been demonstrated in prostate
cancer patients and advanced cancer patients (Tahir et al,
2001); however, in contrast NKT cells of lung cancer and
melanoma patients have been shown to have comparatively
normal a-GalCer proliferative capacity (Kawano et al, 1999a;
Motohashi et al, 2002).
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lOf note, previous studies investigated NKT cells of cancer
patient’s either pretreatment or did not take into account potential
effects of chemotherapy and radiation therapy on NKT cell
numbers and expansion capacity. This is important information
due to the likelihood that NKT cell immunotherapy will be used
secondary to conventional cancer therapies.
For interventions aimed at increasing NKT cells to be effective at
treating malignancy, it is a prerequisite that NKT cells in cancer
patients firstly exist and also retain the ability to respond to
specific stimuli. This study evaluated the effects of age, malignancy
and associated treatment on the numbers of NKT cells in 109
patients with solid organ cancer using 40 healthy individuals as
controls. Responsiveness to a-GalCer stimulation was also assessed
in 28 of the cancer patients and 37 of the healthy donors following
assessment of NKT cell numbers.
MATERIALS AND METHODS
Subject groups and controls
The study group consisted of 109 subjects (64 males and 45
females) with solid organ cancer (median age 58 years, range 26–
82). They were subclassified according to cancer type (colorectal,
breast, melanoma, renal cell carcinoma (RCC), lung, others) and
prior cancer treatment. The control healthy volunteer group
comprised 40 healthy volunteers, 25 females and 15 males (median
age 34 years, range 19–68) with no history of malignant disease.
Natural killer T cell number was assessed in each of the cancer
patients and healthy donor, however only 37 of the healthy donors
and 28 of the cancer patients could be assessed for expansion
capacity following a-GalCer stimulation.
Characteristics of the study group are presented in Table 1.
Peripheral blood samples were collected after obtaining informed
consent from the subjects, and the study was approved by The
Royal Brisbane and Womens Hospital and the Health Services
Districts Human Research Ethics Committee.
Phenotypic analysis
Fresh whole blood or peripheral blood mononuclear cells
(PBMC), separated by Ficoll–Paque (Amersham Pharmacia
Biotech, Uppsala, Sweden) density centrifugation were stained
with fluorescein isothiocyanate (FITC)-conjugated anti-Va24
(IgG1: Cl5), phycoerythrin (PE)-conjugated anti-Vb11 (IgG2a:
C21) and phycoerythrin–cyanin 5.1 (PC5)-conjugated anti-CD3
(IgG1, UCHT1) and analysed by three-colour flow cytometry
using a FACSCalibur (Becton Dickinson, San Diego CA,
USA). Appropriate isotype controls were used and all antibodies
were purchased from Beckman Coulter (Sydney, Australia).
Natural killer T cells were defined as Va24
þVb11
þCD3
þ and
to ensure accuracy of the flow cytometric evaluation up to
1 10
6 cells were assessed in order to acquire 4100 NKT cell
events.
Calculation of NKT cell numbers
Natural killer T cell numbers were expressed as a percentage of the
CD3
þ lymphocyte population as determined by flow cytometry.
To determined the number of NKT cells per litre (l) of blood, the
fraction of lymphocytes that were NKT cells according to flow
cytometry was multiplied by the number of lymphocytes per litre
as determined by an automated full blood count on the same
sample.
Expansion of Va24
þVb11
þ NKT cells
Peripheral blood mononuclear cells were assessed for NKT cell
numbers as described above (Day 0) and cultured at
1 10
6cellsml
 1 in AIM-V medium (Gibco BRL, Melbourne,
Australia) supplemented with 10% normal human AB serum,
10Uml
 1 interleukin-2 (IL-2) (R&D Systems, Sydney, Australia)
and 100ngml
 1 KRN 7000 (a gift from Pharmaceutical Division,
Kirin Brewery, Gumna, Japan) for 7 days. On Day 7, the cells were
harvested, counted and analysed by flow cytometry as described
above and the results are expressed in terms of fold expansion, as
determined from the respective NKT numbers at Day 0 and
following 7 days expansion.
Statistics
Results for NKT cell percentages and absolute numbers of
NKT cells and CD3
þ T cells have been presented as medians
separately for the different cancer groups. Owing to the
large number of zero NKT cell percentage counts, the distribution
was extremely skewed to the right and thus standard normal
distribution-based statistics were not appropriate. For crude
analysis, Kruskal–Wallis nonparametric analysis of variance
was used to compare median NKT cell percentages and
NKTl
 1 between cancer groups. Two-way comparisons between
the various cancer groups and healthy volunteers were performed
using Mann–Whitney U-tests. Both NKT cell percentage and
absolute NKT cell numbers followed an approximately negative-
binomial distribution, and thus negative-binomial regression was
used to evaluate the statistical significance of its association with
tumour status, after adjusting for age and sex differences. The
degree of association between age and NKT cell percentage or
NKTl
 1, age and fold expansion and NKT percentage and fold
expansion were calculated using a Spearman’s nonparametric
correlation coefficient.
Table 1 Characteristics of each group of cancer subjects and normal donors
Sex Treatment history
Subject group n Age range
Median
age Males Females
No prior
treatment
Prior
chemotherapy
Prior
radiation
Prior chemotherapy
and Radiation
Colorectal 33 43–79 61 22 11 13 18 0 3
Breast 10 41–69 54 0 10 1 2 0 7
Other cancers 31 27–72 58 13 18 13 16 1 2
Melanoma 17 26–83 59 14 3 13 1 3 1
Lung cancer 8 33–72 55 6 2 2 2 2 2
RCC 10 36–67 53 9 1 9 0 1 0
All cancer cases 55 26–83 58 64 45 50 39 7 15
Healthy donors 40 19–68 34 15 25 40 NA NA NA
NA¼not applicable.
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lRESULTS
Effect of malignancy on PB NKT cell numbers
Natural killer T cells as a percentage of CD3
þ T cells (NKT %) and
the absolute number of NKT cellsl
 1 of PB were assessed in
healthy donors (n¼40) and cancer patients (n¼109) with a broad
range of malignancies. Natural killer T cells comprised up to 1.27%
of CD3
þ T cells (median value 0.113%) and 9.89 10
6l
 1)o fP Bi n
healthy donors, and up to 1.19% of CD3
þ T cells (median value
0.02%) and 6.52 10
6l
 1 (median value 0.2 10
6l
 1) of PB in all
cancer patients combined (Table 2). No significant difference was
observed between the frequency (P¼0.28) or number (P¼0.06) of
circulating NKT cells in cancer patients and those in healthy
donors after adjusting for age and sex differences. Analysis of the
individual cancer subgroups showed melanoma patients (n¼17)
to have a significantly lower NKT% (median 0.01%, P¼0.04) and
NKTl
 1 (median 0.17 10
6l
 1, P¼0.01), and breast cancer
patients (n¼10) to have a reduced frequency of NKT cells
(median 0.01, P¼0.02) but comparatively similar absolute
numbers of NKT cells (P¼0.13). Total CD3
þ T cellsl
 1 of PB
were significantly lower in all cancer groups with the exception of
colorectal cancer and RCC, indicating that the reduced NKT%
observed in melanoma and breast cancer patients could not be
attributed to increased numbers of total PB T cells.
Impact of prior radiation and/or chemotherapy treatment
on NKT cell numbers
Statistical comparison was conducted between the NKT cell
numbers of all cancer patients who had not undergone previous
chemotherapy or radiation treatment and those who had not
undergone each treatment respectively. No significant difference
was detected between the groups in either comparison, suggesting
that neither radiation nor chemotherapy had an independent effect
on NKT cell numbers in cancer patients when all cancers were
considered collectively (Table 3).
To assess whether chemotherapy or radiation treatment
modulated NKT cell numbers in the individual cancer subgroups,
statistical analysis was conducted for each group following
exclusion of these patients who had previous chemotherapy
(Table 4) or previous radiation therapy (Table 5). As shown in
Table 4, the frequency and absolute number of NKT cell numbers
remained significantly lower in melanoma patients, indicating
chemotherapy was not responsible for the reduction in NKT cells.
However, it must be noted that this result is not unexpected as
chemotherapy is not a common treatment modality for this cancer
type. Conversely, following exclusion of those melanoma patients
with a history of radiation treatment (Table 5), NKT cell numbers
in the group were returned to comparatively healthy levels. This
result suggests that radiation therapy may have a direct effect on
NKT cell numbers in patients with melanoma.
In the instance of breast cancer, there were insufficient patients
in this subgroup following exclusion to ascertain whether prior
treatment was responsible for the decreased NKT % previously
observed. Furthermore, while the significant difference detected
between healthy donors and lung cancer patients with no history
of chemotherapy treatment (P¼0.01) may suggest chemotherapy-
mediated modulation of NKT cell numbers; the low subject
numbers (n¼4) in this subgroup does not facilitate accurate
analysis.
Effect of the ageing process on NKT cell numbers
The percentage and absolute number of circulating NKT cells in
healthy donors weakly but significantly correlated with age such
that NKT % and NKTl
 1 decreased with increasing age (Figure 1,
Table 2 NKT cell percentages, absolute number of NKT cellsl
 1 ( 10
6) and absolute number of CD3
+ T cellsl
 1 ( 10
9) of PB for each study group in
comparison to healthy volunteers
NKT % NKT l 1( 10
6)C D 3
+ T cellsl
 1 ( 10
9)
Subject group n Range Median P-value* Range Median P-value* Range Median P-value*
Colorectal 33 0–0.39 0.012 0.17 0.00–6.53 0.17 0.15 0.19–1.87 1.08 0.06
Breast 10 0–0.15 0.01 0.02 0.00–3.32 0.12 0.13 0.25–2.10 1.00 0.01
Other cancers
a 31 0–1.19 0.04 0.86 0.00–3.24 0.31 0.20 0.16–2.24 0.90 0.003
Melanoma 17 0–0.17 0.01 0.04 0.00–1.61 0.17 0.01 0.25–2.04 0.69 0.004
Lung cancer 8 0–0.26 0.03 0.61 0.00–2.10 0.25 0.09 0.33–1.41 0.85 0.01
RCC 10 0–0.77 0.04 0.66 0.00–1.60 0.52 0.82 0.49–1.74 1.04 0.25
All cancer cases 109 0–1.19 0.02 0.28 0.00–6.53 0.20 0.06 0.16–2.24 0.92 o0.001
Healthy Donors 40 0–1.27 0.11 Reference 0.00–9.89 1.93 NA 0.66–4.52 1.43 Reference
NKT cell percentage is calculated as a percentage of the total CD3
+ T cells as determined by flow cytometry. *P-values compared with healthy donors obtained from negative
binomial regression models adjusted for age and sex differences between study groups.
aOther cancers include liver, adenocarcinoma, prostate, ovarian, uterine and stomach
cancer. NA¼not applicable.
Table 3 Effects of prior radiation and chemotherapy treatment on NKT cell percentages and absolute numbers of NKT cells and CD3
+ T cells in cancer
patients
NKT % NKT l
 1 ( 10
6) CD3l
 1 ( 10
9)
Subject group n Median P-value* Median P-value* Median P-value*
Prior radiation treatment 22 0.02 0.95 0.14 0.28 0.82 0.10
No prior radiation treatment 87 0.02 0.24 1.00
Prior chemotherapy treatment 54 0.02 0.26 0.21 0.26 1.04 0.83
No prior chemotherapy treatment 55 0.03 0.20 0.87
*P-value obtained from negative binomial models adjusting for age and sex differences between the groups.
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litre of blood of cancer patients also appeared to decrease with
increasing age, this correlation proved insignificant (Figure 1,
panels A and B).
Expansion capability of NKT cells in cancer patients and
healthy volunteers – the effect of age and malignancy
Stimulation by a-GalCer resulted in the rapid expansion of NKT
cells from most cancer patients and healthy donors. Figure 2
displays the expansion capacity (fold expansion) of healthy donor
(n¼37) and cancer patient (n¼28) NKT cells in response to in
vitro a-GalCer stimulation. Natural killer T cells of healthy donors
expanded between 0- and 303-fold and those of cancer patients
expanded between 0- and 959-fold. While NKT cells of cancer
patients had an overall reduced capacity to expand (median eight-
fold) as compared to healthy donors (median 43-fold, P¼0.02),
some individual cancer patients were clearly better NKT cell
expanders than healthy donors.
Contrary to the effects of age on NKT numbers in healthy
donors, age did not significantly influence their fold expansion as
displayed in Figure 1C. Although the proliferative potential of
cancer patient NKT cells to a-GalCer appears to decrease
significantly with age, conclusive analysis requires the assessment
of increased numbers of younger cancer patients.
Although NKT cells expanded rapidly from most donors, there
was no relationship between the NKT % in healthy donors and the
degree to which the NKT cells expand. The results do suggest,
however, that NKT % is a reliable indicator of fold expansion in
cancer patients, although the highly skewed nature of the
population towards low NKT % may make the spread of NKT %
too low to determine the correlation accurately. It is of interest that
the largest in vitro NKT cell expansion was observed from donors
with relatively low NKT cell numbers.
DISCUSSION
Clinical application of NKT cells as therapy for malignancy
is critically dependent upon their activation and subsequent
expansion in humans. With the development of therapeutic
approaches with the potential to activate NKT cells in vivo (Nieda
et al, 2003) and expand NKT cells in vitro (Nieda et al, 1999; Nicol
et al, 2000a; Takahashi et al, 2000), it is important to more clearly
define their applicability in the clinical setting. Previous data
indicate that NKT cells may be decreased in some cancer patients
(Kawano et al, 1999a; Tahir et al, 2001; Motohashi et al, 2002). It
this is associated with or caused by decreased responsiveness to
a-GalCer, then these therapies may have less than expected clinical
utilities.
We have confirmed with considerably larger subject numbers in
this study that the percentage of Va24
þ NKT cells in cancer
patients does not significantly differ to that in healthy donors
when all cancer types are considered collectively (Yanagisawa et al,
2002). Our data also support previous reports that NKT cell
numbers are significantly reduced in patients with melanoma
(Kawano et al, 1999a); however, in contrast to Motohashi et al
(2002) decreased frequency and absolute number of NKT cells
was not seen in lung cancer patients. A likely explanation for
this inconsistency is the inclusion of insufficient patients in this
subgroup to detect a statistically significant difference, in view
of the 60 lung cancer patients assessed in the previous study.
As no studies to date have assessed the numbers of NKT
cells in breast cancer patients we have, for the first time,
demonstrated a significantly reduced percentage of NKT cells in
this cancer group.
Reasons for the observed reductions in breast cancer and
melanoma patients are unknown. It is evident that the results are
not simply a consequence of increased total CD3
þ T cell numbers
in either disease (Table 2). Contrary to previous studies, which
have in majority assessed NKT cell levels pretreatment or without
Table 5 NKT cell percentages, absolute number of NKT cells l
 1 ( 10
6) and absolute number of CD3
+ T cells l
 1 ( 10
9) of PB for each study group
excluding subjects who have had prior radiation therapy in comparison to healthy volunteers
Subject group n NKT % P-value* NKT l
 1 ( 10
6) P-value* CD3
+ T cellsl
 1 ( 10
9) P-value*
Colorectal 30 0.016 0.16 0.17 0.14 0.10 0.03
Breast 3 0.005 0.001 0.01 0.02 0.65 0.001
Other cancers
a 28 0.042 0.91 0.32 0.15 1.01 0.003
Melanoma 13 0.018 0.10 0.17 0.02 0.70 0.013
Lung cancer 4 0.055 0.92 0.25 0.12 1.11 0.19
RCC 9 0.04 0.31 0.38 0.12 1.03 0.06
All cancer cases 87 0.02 0.28 0.24 0.24 1.00 0.001
Healthy donors 40 0.113 Reference 1.93 Reference 1.43 Reference
See footnote in Table 2.
Table 4 NKT cell percentages, absolute number of NKT cells l
 1 ( 10
6) and absolute number of CD3
+ T cellsl
 1 ( 10
9) of PB for each study group
excluding subjects who have had prior chemotherapy in comparison to healthy volunteers
Subject group n NKT % P-value* NKT l
 1 ( 10
6) P-value* CD3
+ T cellsl
 1 ( 10
9) P-value*
Colorectal 12 0.016 0.09 0.14 0.22 0.87 0.01
Breast 1 0.000 NA 0.00 NA 0.00 NA
Other cancers
a 13 0.130 0.27 1.33 0.72 1.03 0.06
Melanoma 15 0.010 0.03 0.08 0.002 0.66 o0.001
Lung cancer 4 0.015 0.01 0.17 0.009 0.82 0.03
RCC 10 0.040 0.62 0.52 0.96 1.04 0.09
All cancer cases 55 0.030 0.83 0.20 0.20 0.87 o0.001
Healthy donors 40 0.113 Reference 1.93 NA 1.43 Reference
See footnote in Table 2.
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Figure 1 Association of age on proportion of NKT cells (NKT %; A), absolute numbers of circulating NKT cells (NKTl
 1; B) and responsiveness to a-
GalCer (C) in cancer patients and healthy donors. (D) represents the correlation between NKT cell numbers and NKT cell expansion capacity.
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lindicating prior treatment, we have taken into consideration
potential effects of chemotherapy or radiation treatment on NKT
cell numbers. We have identified that radiation treatment may be
directly responsible for the decreased NKT cell numbers in
melanoma patients. It remains possible, however, that a disease-
specific effect by melanoma may still contribute to the observed
reduction and although not examined in this study, decreases in
NKT cell numbers could also be due to an accumulation of NKT
cells at tumour sites, thus decreasing their overall number in the
circulating PB. This, together with longitudinal studies, aimed at
ascertaining whether the low NKT cells numbers in these patients
predated the manifestation of cancer, would help further the
understanding of the relationship between NKT cell numbers and
cancer.
There were insufficient subject numbers to ascertain treatment-
related effects on NKT cells breast cancer patients, and indications
that chemotherapy modulates NKT cell numbers in lung cancer
patients cannot be conclusively determined with the subject
numbers available in this subgroup.
The effect of the ageing process on NKT cell numbers has only
been assessed in a singly study (DelaRosa et al, 2002). In
accordance with that study, we showed a decreased percentage
of Va24
þ NKT cells in healthy elderly individuals. We have
also demonstrated that absolute NKT cell numbers decrease
significantly with age in healthy donors. A similar trend
was observed in cancer patients, however the statistical signifi-
cance (P¼0.06) was potentially influenced by a concentration
of middle- to late-aged cancer patients. Although greater numbers
of younger cancer patients are required to assess this association
accurately, the results do raise the possibility that low NKT
cells may be a risk factor for cancer in young adults. They also
confirm that in consideration of their intrinsically low NKT cell
numbers, middle and older aged cancer patients could benefit
greatly from therapeutic manipulations that boost their NKT cell
numbers.
The magnitude of NKT cell activation and expansion may have
critical consequences on the efficacy of NKT cell therapies. We and
others have shown that NKT cells of cancer patients can be
dramatically expanded by a-GalCer stimulation, however to levels
lower that that of healthy donors (Tahir et al, 2001). Studies of
melanoma and lung cancer patients have in contrast reported NKT
cells with comparatively normal capacities to expand (Kawano
et al, 1999a; Motohashi et al, 2002). As we could not assess in vitro
NKT expansion on every cancer subject involved, we cannot
determine whether NKT cell expansion is reduced in every cancer
type, or whether the overall result is influenced by one or several
subgroups of cancer patients.
Mechanisms of reduced responsiveness of NKT cells to a-GalCer
stimulation have not been determined. Immune defects and
dysfunction in T cells and the antigen presenting and stimulatory
capacity of DC have previously been reported in cancer patients
(Mizoguchi et al, 1992; Goto et al, 1999; Kiessling et al, 1999;
Ninomiya et al, 1999). As in vitro expansion capacity is dependent
upon both the number and stimulatory capacity of CDld antigen-
presenting cells, reduced numbers of and/or functionally defective
CDld APC may suppress NKT activation in cancer patients.
Production of immunosuppressive factors by tumour cells or TGF-
b by CD3
þ T cells or intrinsic defects to the NKT cells themselves
may also inhibit their expansion potential (Tada et al, 1991;
Chouaib et al, 1997).
While functional impairment as a consequence of age has been
reported to occur in other cell types such as T cells (Hakim et al,
2004; Plackett et al, 2004), there appears no association between
the functional capacity of an NKT cell to respond to a-GalCer and
the age of the healthy donor. Although fold expansion significantly
decreased with age in cancer patients, this result was dependent
upon three individuals with particularly high expansion. Con-
firmation of this latter observation would require the inclusion of
an increased numbers of younger cancer patients in the subject
group.
The precise relationship, if any, between the proportion of
NKT cells in a donor and the NKT cell’s functional capacity to
expand has to date not been examined. While we have shown
that there is no association between the percentage of NKT cells
and fold expansion in normal donors, it is clearly evident that
the largest degree of expansion was in donors with an NKT
cell % at the lower end of the scale. Although fold expansion
significantly increased with NKT % in cancer patients, the highly
skewed nature of the population towards low NKT % makes
the spread of this variable too narrow to accurately determine the
correlation. NKT cells capable of dramatic expansion, some
that exceeded values seen in normal donors were also prevalent
within the cancer patient group. These data go a significant
way to disproving the assumption held by some that people
with low NKT cells will have NKT cells defective for in vitro
expansion potential. It will be interesting to determine through
clinical trials whether this translates to in vivo NKT cell expansion
and whether this group of patients would benefit most from
clinical interventions aimed at the in vivo activation and expansion
of NKT cells.
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Figure 2 Expansion capacity of NKT cells in normal donors (n¼37) and
cancer patients (n¼28) in response to a-GalCer stimulation (line indicates
median of group). Natural killer T cells can rapidly expand in both groups,
however overall to a significantly lower degree in cancer patients
(P¼0.02).
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lIn summary, our study demonstrates that NKT cell numbers and
their activation and capacity can be modulated by both age and
malignancy and in contrast to previous studies, conventional
cancer treatment. Whilst further studies are required to determine
both the stage at which treatment or malignant disease leads to
decreased NKT cell numbers and the mechanism by which cancer
affects impacts NKT cell function, our results provide important
information for the clinical trials involving in vivo activation or
large-scale in vitro expansion of NKT cells.
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